COPENHAGEN, Denmark, May 30, 2024 /PRNewswire/ Vesper Bio ApS ("Vesper" or "the Company"), a clinical stage biotech and world leader in sortilin receptor biology, today announces completion
(MENAFN - PR Newswire) Vesper Bio, backed byLundbeckfonden BioCapital, initiates a Phase I study to evaluate its lead asset VES001, for the treatment of FTD (GRN mutation), addressing a critical . .
Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia (FTD) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NMD Pharma from Denmark secures €75M Series B to advance novel treatments for neuromuscular diseases arcticstartup.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arcticstartup.com Daily Mail and Mail on Sunday newspapers.